Astellas Misses Again On Xospata Label Expansion Effort
A Phase III disappointment in a maintenance therapy setting for FLT3-mutated acute myeloid leukemia is yet another failed attempt by Astellas to add to Xospata’s label since US FDA approval in 2018.
You may also be interested in...
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
A Dramatically Changing Landscape In Acute Myeloid Leukemia
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
Astellas' Phase III Front-Line AML Study Of Xospata Fails
One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.